News stories about Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a news impact score of 0.19 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.1699946977048 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Investors may need a consensus Analysts Rating: Aurinia Pharmaceuticals Inc. (AUPH) – Wall Street Morning (wallstreetmorning.com)
- Investors may need a consensus Analysts Rating: Aurinia … – Wall Street Morning (wallstreetmorning.com)
- Aurinia Pharmaceuticals Inc (AUPH) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Attention Seeking Stock – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) – The Investor Guide (wallstreetnews24.com)
- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) – Here’s What to Focus on – Nasdaq Journal (press release) (nasdaqjournal.com)
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at $5.35 on Friday. Aurinia Pharmaceuticals has a 12 month low of $2.30 and a 12 month high of $10.54. The stock has a market cap of $441.70, a P/E ratio of -4.42 and a beta of 2.34.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. Aurinia Pharmaceuticals had a negative return on equity of 25.56% and a negative net margin of 18,089.02%. Aurinia Pharmaceuticals’s quarterly revenue was up .0% compared to the same quarter last year. analysts expect that Aurinia Pharmaceuticals will post -1.05 earnings per share for the current fiscal year.
A number of brokerages have issued reports on AUPH. BidaskClub upgraded shares of Aurinia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, January 5th. Zacks Investment Research downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. ValuEngine raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Canaccord Genuity set a $11.00 price objective on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 17th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 15th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $10.79.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.